Eisai Co., LTD. to License Incyte Genomics LifeSeq® Gold Online Palo Alto, CA, and Tokyo, Japan, April 9, 2001 -- Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomic information company, and Eisai Co., Ltd., today announced the signing of a multi-year subscription for Incyte's industry leading LifeSeq® Gold database to advance Eisai's healthcare research initiatives. In addition, Eisai will subscribe to Incyte's ZooSeq™ animal model database. Financial terms were not disclosed. The LifeSeq Gold database provides researchers with the most comprehensive view of the entire human genome by integrating proprietary expressed tag sequence (EST) and full-length gene sequence information, mapping data, in addition to public genomic sequence information. The database contains more than 120,000 transcribed, or expressed, genes of which approximately half are not commercially available elsewhere. As a LifeSeq Gold subscriber, Eisai will have access to Incyte's full-length gene program in addition to high-quality sequence-verified cDNA clones, or copies of genes, for conducting further research in the lab. Eisai is committed to innovative health care for patients and their families around the world. Researchers at Eisai will have around the clock access to Incyte's powerful data processing capabilities and experienced IT professionals to manage the database by accessing the LifeSeq Gold database online. Incyte's online LifeSeq Gold and ZooSeq offerings provide full confidentiality for users, and features encryption protection used in online banking and credit card transactions to protect the security of all queries and personal information. "We are pleased to be working with Eisai which is one of Japan's most committed and respected firms dedicated to healthcare," said Roy A. Whitfield, Chief Executive Officer of Incyte. "LifeSeq Gold online will enable researchers at Eisai to utilize Incyte's vast computer processing power, and benefit from our industry leading position in generating and managing genomic information." "To realize our goal as a leader in the development of innovative therapies, we recognize that genome-based research is an integral component in today's drug discovery and when we completed our analysis of the various genomic data product offerings, we became convinced that the collaboration with Incyte Genomics will greatly strengthen our genome-based research activities," said Aishin Shinoda, Senior Vice President of Eisai Co., Ltd. Eisai Co., Ltd. is a research-based human health care company, which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 7,000 people worldwide. Eisai common stock is listed on the Tokyo Stock Exchange and the Osaka Securities Exchange. For additional information, visit Eisai's web site at http://www.eisai.co.jp. Incyte Genomics, Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's web site at http://www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, including statements as to the role of Incyte's products, proprietary technology and database information in third-party research programs and the extent to which genome-based research will assist researchers in their drug discovery efforts, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the extent to which genomic databases are utilized in pharmaceutical research and development; the ability of Incyte to provide products and services that meet market needs; the impact of competition and alternative technologies, processes and approaches; and other risks detailed from time to time in Incyte's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2000. These forward-looking statements speak only as of the date hereof. Incyte disclaims any intent or obligation to update these forward-looking statements.